Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX 77030, USA.
Nat Rev Clin Oncol. 2012 Jul 3;9(8):471-8. doi: 10.1038/nrclinonc.2012.99.
Our understanding of the biology of cancer and the application of this knowledge to cancer treatment has greatly outpaced what we know of the biology underlying the symptoms and toxic effects that therapies produce. These adverse effects of therapy cause substantial discomfort and distress to patients and their families, limit treatment tolerability and can persist indefinitely in post-treatment survivorship. Despite these concerns, little research effort is targeted at documenting the nature of these effects. Similarly, limited efforts are being made in the drug-development arena to identify or develop treatments that might prevent or reduce toxicities. A panel of clinicians and researchers as well as representatives from advocacy groups, federal agencies and the pharmaceutical industry was convened to identify gaps in cancer treatment toxicity research and to provide direction for future action. With an emphasis on coordinating multidisciplinary efforts, this panel has presented a strategy to increase funding for the field and develop a coherent research agenda.
我们对癌症生物学的理解以及将这些知识应用于癌症治疗已经大大超过了我们对治疗产生的症状和毒性的生物学基础的了解。这些治疗的不良反应会给患者及其家属带来极大的不适和痛苦，限制了治疗的耐受性，并且在治疗后生存期间可能会无限期地持续存在。尽管存在这些问题，但针对记录这些影响的性质的研究工作很少。同样，在药物开发领域，也很少有努力来确定或开发可能预防或减少毒性的治疗方法。召集了一组临床医生和研究人员以及来自倡导团体、联邦机构和制药行业的代表，以确定癌症治疗毒性研究中的差距，并为未来的行动提供指导。该小组强调协调多学科努力，提出了一项增加该领域资金并制定连贯研究议程的战略。
